Hikma Pharmaceuticals PLC

OTCPK:HKMP.F Stock Report

Market Cap: US$4.2b

Hikma Pharmaceuticals Valuation

Is HKMP.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of HKMP.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: HKMP.F ($19.29) is trading below our estimate of future cash flow value ($55.32)

Significantly Below Future Cash Flow Value: HKMP.F is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HKMP.F?

Key metric: As HKMP.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for HKMP.F. This is calculated by dividing HKMP.F's market cap by their current earnings.
What is HKMP.F's PE Ratio?
PE Ratio10.4x
EarningsUS$402.00m
Market CapUS$4.20b

Price to Earnings Ratio vs Peers

How does HKMP.F's PE Ratio compare to its peers?

The above table shows the PE ratio for HKMP.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average27.1x
INDV Indivior Pharmaceuticals
18.4x13.84%US$4.6b
AMRX Amneal Pharmaceuticals
42.5x42.90%US$5.2b
OGN Organon
14.3x30.56%US$3.5b
LGND Ligand Pharmaceuticals
33.3x16.99%US$5.1b
HKMP.F Hikma Pharmaceuticals
10.4x8.71%US$3.1b

Price-To-Earnings vs Peers: HKMP.F is good value based on its Price-To-Earnings Ratio (10.4x) compared to the peer average (27.1x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does HKMP.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

6 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NDOI Endo
0.3xn/aUS$1.76b
ORMP Oramed Pharmaceuticals
1.4xn/aUS$157.16m
SDEV Stablecoin Development
0.06xn/aUS$29.28m
OWPC One World Products
0.2xn/aUS$731.12k
HKMP.F 10.4xIndustry Avg. 15.1xNo. of Companies6PE01224364860+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: HKMP.F is good value based on its Price-To-Earnings Ratio (10.4x) compared to the US Pharmaceuticals industry average (15.1x).

Price to Earnings Ratio vs Fair Ratio

What is HKMP.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HKMP.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio10.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate HKMP.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HKMP.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$25.52
0%
16.76%US$35.45US$18.17n/a11
Jun ’27US$19.95
US$25.52
+27.97%
16.76%US$35.45US$18.17n/a11
May ’27n/a
US$25.47
0%
16.98%US$35.45US$18.17n/a11
Apr ’27n/a
US$25.36
0%
16.99%US$35.47US$18.17n/a11
Mar ’27US$18.00
US$28.71
+59.49%
13.55%US$35.47US$21.60n/a11
Feb ’27US$20.92
US$29.74
+42.14%
11.13%US$34.40US$21.60n/a11
Jan ’27US$20.94
US$30.30
+44.71%
7.80%US$34.40US$26.37n/a11
Dec ’26n/a
US$30.64
0%
8.65%US$34.73US$26.37n/a11
Nov ’26US$24.32
US$33.57
+38.06%
7.62%US$37.47US$29.11n/a11
Oct ’26US$22.46
US$33.78
+50.39%
7.95%US$38.52US$29.11n/a11
Sep ’26US$24.50
US$33.93
+38.49%
7.20%US$38.52US$29.11n/a11
Aug ’26US$26.38
US$34.70
+31.53%
8.81%US$41.85US$29.01n/a11
Jul ’26n/a
US$34.56
0%
8.78%US$41.85US$29.01n/a11
Jun ’26n/a
US$33.60
0%
11.05%US$41.10US$26.62US$19.9510
May ’26n/a
US$32.80
0%
11.45%US$41.23US$26.62n/a10
Apr ’26n/a
US$31.59
0%
12.59%US$40.16US$25.25n/a10
Mar ’26US$27.17
US$30.90
+13.70%
11.54%US$38.94US$25.25US$18.0010
Feb ’26n/a
US$29.74
0%
12.92%US$38.94US$24.38US$20.9210
Jan ’26n/a
US$29.78
0%
12.52%US$38.94US$25.15US$20.9410
Dec ’25US$24.47
US$29.70
+21.36%
12.27%US$38.94US$25.54n/a10
Nov ’25n/a
US$29.90
0%
8.69%US$35.15US$25.54US$24.3210
Oct ’25n/a
US$30.39
0%
10.67%US$36.99US$25.54US$22.4611
Sep ’25US$25.96
US$29.86
+15.01%
11.57%US$36.99US$25.54US$24.5011
Aug ’25US$24.00
US$28.98
+20.76%
13.24%US$36.20US$23.92US$26.3811
Jul ’25n/a
US$28.93
0%
13.41%US$36.20US$23.92n/a11
Jun ’25n/a
US$28.69
0%
13.34%US$35.33US$23.58n/a11
US$24.65
Fair Value
21.7% undervalued intrinsic discount
11
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/17 06:07
End of Day Share Price 2026/06/03 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hikma Pharmaceuticals PLC is covered by 27 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sidhartha ModiBarclays
James GordonBarclays
Beatrice FairbairnBerenberg